AstraZeneca and Voluntis to test digital support service in ovarian cancer trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Voluntis announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. The service has been developed by Voluntis in clinical collaboration with AstraZeneca and NCI. It is delivered through a smartphone app paired with a web portal to...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login